BG102474A - (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат - Google Patents

(-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат

Info

Publication number
BG102474A
BG102474A BG102474A BG10247498A BG102474A BG 102474 A BG102474 A BG 102474A BG 102474 A BG102474 A BG 102474A BG 10247498 A BG10247498 A BG 10247498A BG 102474 A BG102474 A BG 102474A
Authority
BG
Bulgaria
Prior art keywords
phenyl
tetrahydronaphthalen
tartarate
cis
yletoxi
Prior art date
Application number
BG102474A
Other languages
English (en)
Other versions
BG63943B1 (bg
Inventor
Charles Chiu
Morgan Meltz
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG102474A publication Critical patent/BG102474A/bg
Publication of BG63943B1 publication Critical patent/BG63943B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до метод за получаване на(-)-цис-6(S)-фенил-5(R)-[4-(2-пиролидин-1-илетокси)фенил]-5,6,7,8-тетрахидронафтален-2-ол-D-тартарат.
BG102474A 1995-11-02 1998-05-21 (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат BG63943B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US612595P 1995-11-02 1995-11-02
PCT/IB1996/001049 WO1997016434A1 (en) 1995-11-02 1996-10-04 (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate

Publications (2)

Publication Number Publication Date
BG102474A true BG102474A (bg) 1999-06-30
BG63943B1 BG63943B1 (bg) 2003-07-31

Family

ID=21719433

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102474A BG63943B1 (bg) 1995-11-02 1998-05-21 (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат

Country Status (43)

Country Link
US (1) US5948809A (bg)
EP (1) EP0876359B1 (bg)
JP (1) JP3088020B2 (bg)
KR (1) KR19990067280A (bg)
CN (1) CN1067065C (bg)
AP (1) AP713A (bg)
AR (1) AR004078A1 (bg)
AT (1) ATE248827T1 (bg)
AU (1) AU708841B2 (bg)
BG (1) BG63943B1 (bg)
BR (1) BR9611436A (bg)
CA (1) CA2236673C (bg)
CO (1) CO4770967A1 (bg)
CZ (1) CZ287341B6 (bg)
DE (1) DE69629837T2 (bg)
DK (1) DK0876359T3 (bg)
DZ (1) DZ2114A1 (bg)
EG (1) EG21095A (bg)
ES (1) ES2203713T3 (bg)
GT (1) GT199600085A (bg)
HR (1) HRP960503B1 (bg)
HU (1) HU227521B1 (bg)
IL (1) IL124027A (bg)
IS (1) IS1855B (bg)
MA (1) MA23998A1 (bg)
NO (1) NO310358B1 (bg)
NZ (1) NZ318498A (bg)
OA (1) OA11009A (bg)
PE (1) PE17698A1 (bg)
PL (1) PL188633B1 (bg)
PT (1) PT876359E (bg)
RO (1) RO119829B1 (bg)
RU (1) RU2162465C2 (bg)
SI (1) SI0876359T1 (bg)
SK (1) SK282172B6 (bg)
TN (1) TNSN96134A1 (bg)
TR (1) TR199800783T2 (bg)
TW (2) TW518327B (bg)
UA (1) UA51676C2 (bg)
UY (1) UY24362A1 (bg)
WO (1) WO1997016434A1 (bg)
YU (1) YU49123B (bg)
ZA (1) ZA969212B (bg)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
DK0966968T3 (da) * 1998-06-16 2004-08-30 Pfizer Prod Inc Terapeutiske kombinationer, der omfatter en selektiv östrogenreceptormodulator og prostaglandin E2
IL139587A0 (en) * 1998-06-16 2002-02-10 Pfizer Prod Inc Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
PA8475901A1 (es) * 1998-06-16 2000-05-24 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
JP2004510693A (ja) 2000-04-07 2004-04-08 ファイザー・プロダクツ・インク エストロゲンアゴニスト／アンタゴニスト代謝物
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
OA12596A (en) 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
HUP0401268A2 (hu) 2001-07-31 2004-11-29 Pfizer Products Inc. Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
EP1487790B1 (en) * 2002-03-28 2010-03-03 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
BRPI0512342A (pt) * 2004-06-21 2008-03-04 Pharmacia & Upjohn Co Llc métodos para aumento ósseo
JP2008505075A (ja) * 2004-06-30 2008-02-21 イーライ リリー アンド カンパニー １−（インドール−６−カルボニル−ｄ−フェニルグリシニル）−４−（１−メチルピペリジン−４−イル）ピペラジンｄ−酒石酸塩
DE602006017217D1 (de) * 2005-06-22 2010-11-11 Pfizer Prod Inc Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)-phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin-hydrochlorid
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US8937188B2 (en) 2009-04-29 2015-01-20 Glenmark Generics Ltd. Process for the preparation of lasofoxifene tartrate
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
HRP960503A2 (en) 1998-04-30
PL326498A1 (en) 1998-09-28
IS4718A (is) 1998-04-16
GT199600085A (es) 1998-04-04
ES2203713T3 (es) 2004-04-16
YU57896A (sh) 1998-12-23
HU227521B1 (en) 2011-07-28
US5948809A (en) 1999-09-07
TR199800783T2 (xx) 1998-08-21
HUP9900087A2 (hu) 1999-05-28
JP3088020B2 (ja) 2000-09-18
AU6998496A (en) 1997-05-22
MA23998A1 (fr) 1997-07-01
YU49123B (sh) 2004-03-12
CN1201458A (zh) 1998-12-09
CO4770967A1 (es) 1999-04-30
NO310358B1 (no) 2001-06-25
UA51676C2 (uk) 2002-12-16
WO1997016434A1 (en) 1997-05-09
AP9600880A0 (en) 1997-01-31
PL188633B1 (pl) 2005-03-31
BR9611436A (pt) 1999-03-23
PT876359E (pt) 2003-12-31
RO119829B1 (ro) 2005-04-29
EP0876359B1 (en) 2003-09-03
HUP9900087A3 (en) 1999-11-29
TW581766B (en) 2004-04-01
ZA969212B (en) 1998-05-04
RU2162465C2 (ru) 2001-01-27
AR004078A1 (es) 1998-09-30
CA2236673A1 (en) 1997-05-09
DE69629837T2 (de) 2004-05-06
SK282172B6 (sk) 2001-11-06
EG21095A (en) 2000-10-31
CZ287341B6 (en) 2000-10-11
PE17698A1 (es) 1998-04-18
NO981962D0 (no) 1998-04-30
SK54298A3 (en) 1999-07-12
SI0876359T1 (en) 2003-12-31
DK0876359T3 (da) 2003-11-24
EP0876359A1 (en) 1998-11-11
OA11009A (en) 2003-03-03
TNSN96134A1 (fr) 1998-12-31
AU708841B2 (en) 1999-08-12
IS1855B (is) 2003-02-21
UY24362A1 (es) 1997-04-24
CN1067065C (zh) 2001-06-13
NO981962L (no) 1998-04-30
DZ2114A1 (fr) 2002-07-22
IL124027A (en) 2001-10-31
MX9803544A (es) 1998-09-30
CZ132098A3 (cs) 1999-03-17
KR19990067280A (ko) 1999-08-16
TW518327B (en) 2003-01-21
DE69629837D1 (de) 2003-10-09
JPH11502866A (ja) 1999-03-09
NZ318498A (en) 1999-06-29
HRP960503B1 (en) 2001-12-31
CA2236673C (en) 2002-03-19
BG63943B1 (bg) 2003-07-31
AP713A (en) 1998-12-28
ATE248827T1 (de) 2003-09-15

Similar Documents

Publication Publication Date Title
BG102474A (bg) (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат
MX9603050A (es) Derivados de la 1-h-3-aril-pirrolidin-2,4-diona como agentes pesticidas.
MX9606203A (es) Derivados heterociclicos sustituidos.
PL322249A1 (en) 1,4,5-substituted derivatives of imidazole useful as cytokin inhibitors
BG101833A (bg) Гуаниново производно
CA2092083A1 (en) Herbicidal substituted aryl-haloalkylpyrazoles
AU2959995A (en) Stereochemical wortmannin derivatives
AU5554198A (en) 3-thiocarbamoylpyrazole derivatives as pesticides
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
AU3631197A (en) N-benzylpiperidine and tetrahydropyridine derivatives
GR3036305T3 (en) Chiral methyl phenyl oxazolidinones
ES8704931A1 (es) Un procedimiento para la preparacion de derivados de piridimilmidazolidiona.
AU3498789A (en) Process for making 1,3-diols from epoxides
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
MY105128A (en) Bu-3608 derivatives.
BG103649A (bg) Метод за получаване на епросартан
MX9706744A (es) Proceso novedosos para preparar derivados de 2,3-dihidro-benzofuranol.
AU8631698A (en) A process for the preparation of tetraazamacrocycles
BG103650A (bg) Метод за получаване на епросартан
ZA976854B (en) Treatment of psychotic disorders.
HU228274B1 (en) Intermediates for the preparation of 2-imidazoline-5-ones
EP0169051A3 (en) Pyridazinylurea compounds
IL158356A0 (en) Benzoheterocycles
GB9602866D0 (en) Novel process